AXIM Biotechnologies AXIM, developers of cannabinoid-based pharmaceutical and cosmetic products, announced the production of CanChew Plus.
CanChew Plus is an upgrade from AXIM's original CanChew, which the company calls "the most well-known cannabis gum product on the market." While the fate of recreational marijuana use has come into question, marijuana stocks as a whole have been on a high in 2017.
Features of CanChew Plus, which is currently in a clinical trial in the Netherlands for the treatment of irritable bowel syndrome, include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Comes in a delicious new spearmint flavor
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
In a press release, AXIM says CanChew Plus contains the same active ingredients and is designed to be 60% smaller than the original CanChew.
Shares of AXIM were down 5.64 percent Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.